Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Clemens Leitgeb"'
Autor:
Wolfgang Hilbe, Veronika Seebacher, Ewald Wöll, Kira Brämswig, Franz Romeder, Clemens Leitgeb, Thomas Kühr, Alexandra Martel, Andreas L. Petzer, Thomas Brodowicz, Michael Girschikofsky, Brigitte Mlineritsch, Ferdinand Ploner, Gerhard Hochreiner, Thomas Bauernhofer, S. Ressler, Herbert Stöger
Publikováno v:
Anti-cancer drugs. 25(7)
Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b749da502444a9034b27803ac6da2f
https://pubmed.ncbi.nlm.nih.gov/24667659
https://pubmed.ncbi.nlm.nih.gov/24667659
Autor:
Richard Greil, Werner Linkesch, Ludek Pour, Clemens Leitgeb, Adelheid Seebacher, Adalbert Weißmann, Elisabeth Rauch, Heinz Ludwig, Zdeněk Adam, Niklas Zojer, Hedwig Kasparu
Publikováno v:
Blood. 123(7)
Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 years, and patients had a median of 2 prior treatment lines (range, 1 to 6 lines). Bendamustine 70 mg/m(2) days 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1dfa6d77cc086e506c5bb69b990627
https://pubmed.ncbi.nlm.nih.gov/24526773
https://pubmed.ncbi.nlm.nih.gov/24526773
Autor:
Elke Fritz, Heinz Ludwig, Judith Schuster, Martin Pecherstorfer, Hellmut Samonigg, Clemens Leitgeb
Publikováno v:
Blood. 84:1056-1063
Chronic anemia of cancer can be corrected in approximately 50% of the cases by treatment with recombinant human erythropoietin (rHuEPO). Early prediction of responsiveness would avoid the emotional and financial burden of ineffective medical interven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06736b665f9327ee2390e653f6bb787d
https://doi.org/10.1182/blood.v84.4.1056.bloodjournal8441056
https://doi.org/10.1182/blood.v84.4.1056.bloodjournal8441056
Publikováno v:
STEM CELLS. 11:348-355
Recombinant human erythropoietin (rHuEPO) improves chronic anemia of cancer, but the proportion of patients who respond favorably to the treatment varies depending on the type of neoplasia. Preliminary data of the two malignancies with the highest re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fc77dea282ebeba6cc30ca4e2d85ac5
https://doi.org/10.1002/stem.5530110502
https://doi.org/10.1002/stem.5530110502
Autor:
Even Sundal, Thomas Bauernhofer, Andreas Beinhauer, Elke Fritz, Heinz Ludwig, Hellmut Samonigg, Andreas W. Kappeler, Martin Pecherstorfer, Clemens Leitgeb
Publikováno v:
Cancer. 76(11)
Background. Chronic anemia is a common complication in patients with cancer, especially in those with advanced disease or who are under intensive chemotherapy. Because homologous blood transfusions involve some hazards, the safety and efficacy of rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28eb9d7b968a1ba3a91ebbc2b08e3edc
https://pubmed.ncbi.nlm.nih.gov/8780558
https://pubmed.ncbi.nlm.nih.gov/8780558
Autor:
Werner Linkesch, Thomas Kühr, Ludek Pour, Heinz Ludwig, Hedwig Kasparu, Zdenek Adam, Richard Greil, Ercan Müldür, Eva Maria Autzinger, Niklas Zojer, Elisabeth Rauch, Clemens Leitgeb
Publikováno v:
Blood. 120:943-943
Abstract 943 Introduction: Bendamustine has emerged as attractive treatment option for low grade lymphomas and seems to exert synergistic activity with bortezomib. Here we evaluate the efficacy and tolerance of bendamustine in combination with bortez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cddff758ecdd2142a7696442fae2444b
https://doi.org/10.1182/blood.v120.21.943.943
https://doi.org/10.1182/blood.v120.21.943.943
Publikováno v:
Cancer. 73(10)
Background. Improvements in quality of life after treatment with recombinant human erythropoietin (rHuEPO) often have been reported in patients with endstage renal disease. In patients with chronic anemia of cancer, comparatively few systemic investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7892b00f47120cf50025057b48193458
https://pubmed.ncbi.nlm.nih.gov/8174050
https://pubmed.ncbi.nlm.nih.gov/8174050
Autor:
Richard Greil, Werner Linkesch, Zdenek Adam, Clemens Leitgeb, Ludek Pour, Daniel Heintel, Hedwig Kasparu, Adelheid Seebacher, Elisabeth Rauch, Niklas Zojer, Heinz Ludwig, Josef Thaler
Publikováno v:
Blood. 118:2928-2928
Abstract 2928 Introduction: Bendamustine, an alkylating drug with purine like activities may exert synergistic activity in combination with bortezomib. Here we analyze the efficacy and tolerance of bortezomib-bendamustine-dexamethasone with particula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f2299fba625ad79d15e74dfb3889661
https://doi.org/10.1182/blood.v118.21.2928.2928
https://doi.org/10.1182/blood.v118.21.2928.2928